首頁 > 市場調查報告書 > 製藥

呼吸器

市場調查報告書

商品編碼

2084692

間質性肺病市場：依疾病類型、藥物類型、通路和地區分類

Interstitial Lung Disease Market, By Disease Type, By Drug Type, By Distribution Channel, By Geography

出版日期: 2026年06月23日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

間質性肺病市場預計到 2026 年將達到 45 億美元，預計到 2033 年將達到 72 億美元。預計從 2026 年到 2033 年，該市場將以 6.8% 的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	45億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	6.80%	2033年市場規模預測：	72億美元

間質性肺病（ILD）是指一系列導致肺部疤痕（纖維化）的疾病。這種瘢痕會使肺部變硬，導致呼吸困難並影響血液的氧氣供應。長期暴露於有害物質（如石棉）可引起間質性肺病。此外，一些自體免疫疾病，例如類風濕性關節炎，也可能導致間質性肺病。間質性肺病的症狀包括以下幾點：

靜止時呼吸困難。
乾咳。

間質性肺病包括間質性肺炎、特發性肺纖維化、非特異性間質性肺炎、過敏性肺炎、原因不明的機化性肺炎（COP）、類肉瘤病、急性間質性肺炎。間質性肺部疾病（ILD）可使用皮質類固醇、抗纖維化藥物、Pirfenidone和尼達尼布等藥物進行治療。

市場動態

預計在預測期內，監管機構批准的藥物數量增加將推動全球間質性肺病市場成長。例如，2014年10月，美國食品藥物管理局（FDA）批准Pirfenidone（Esbriet）和尼達尼布（Ofev）用於治療特發性肺纖維化（IPF），這是一種進行性且致命的肺部疾病，會導致呼吸窘迫和不可逆的肺損傷。

預計新藥上市數量的增加將推動全球間質性肺病市場的成長。例如，2020年10月，以研發主導的全球綜合製藥公司Glenmark Pharmaceuticals宣佈在印度推出用於治療肺纖維化的藥物nindanib（nindanib 100毫克和150毫克膠囊）。

本次調查的主要特點

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新藥上市和核准、區域前景以及領導企業採取的競爭策略。
本研究根據以下參數介紹了全球間質性肺病市場主要參與者的概況：公司概況、財務表現、產品系列、企業發展區域、分銷策略、主要發展和策略以及未來計劃。
本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、技術升級、市場擴張和行銷策略做出明智的決策。
這份「全球間質性肺病市場報告」旨在為該行業的各種相關人員提供服務，包括投資者、供應商、製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過利用間質性肺病市場分析中使用的各種策略矩陣來簡化決策過程。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第8章競爭情勢

熱圖分析
市佔率分析
公司簡介
- MSD（Merck）
- Liminal Biosciences
- Glenmark Pharma
- B. Chemicals & Pharmaceuticals
- Boehringer Ingelhim International GmbH
- F. Hoffmann-La Roche Ltd.
- Cipla
分析師意見

第9章

參考
調查方法
關於本公司

簡介目錄

Product Code: CMI4798

Interstitial Lung Disease Market is estimated to be valued at USD 4.5 Bn in 2026 and is expected to reach USD 7.20 Bn by 2033, growing at a compound annual growth rate (CAGR) of 6.8% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 4.5 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	6.80%	2033 Value Projection:	USD 7.20 Bn

Interstitial lung disease (ILD) is a term used for group of diseases that cause scarring (fibrosis) of the lungs. This scarring causes stiffness in the lungs, which makes difficult to breathe and supply oxygen to the bloodstream. Interstitial lung disease can be caused due to long-term exposure to hazardous materials such as asbestos. Some types of autoimmune diseases, such as rheumatoid arthritis, also can cause interstitial lung disease. The symptoms of interstitial lung disease include:

Shortness of breath at rest
Dry cough

The diseases which are grouped under interstitial lung disease are interstitial pneumonia, idiopathic pulmonary fibrosis, nonspecific interstitial pneumonitis, hypersensitivity pneumonitis, cryptogenic organizing pneumonia (COP), sarcoidosis, and acute interstitial pneumonitis. Interstitial lung disease (ILD) can be treated with medications such as corticosteroids, anti-fibrotic medication, Pirfenidone, and nintedanib.

Market Dynamics

Increasing number of drug approvals from regulatory bodies is expected to drive the growth of global interstitial lung disease market during the forecast period. For instance, in October 2014, the U.S. Food and Drug Administration (FDA) approved pirfenidone (Esbriet) and nintedanib (Ofev) for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease that makes breathing difficult and causes irreversible lung damage.

Increasing number of drug launches is expected to drive the growth of global interstitial lung disease market. For instance, in October 2020, Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, announced the launch of NINDANIB (Nintedanib 100 and 150 mg capsules) for the treatment of pulmonary fibrosis in India.

Key features of the study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global interstitial lung disease market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
Key companies covered as a part of this study include MSD (Merck), Liminal Biosciences, Glenmark Pharma, J.B. Chemicals & Pharmaceuticals, Boehringer Ingelhim International GmbH, F. Hoffmann-La Roche Ltd., and Cipla
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global interstitial lung disease market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision making through various strategy matrices used in analyzing the interstitial lung disease market.

Market Segmentation

By Disease Type (Revenue, USD Bn, 2021-2033)
Interstitial Pneumonia
Idiopathic Pulmonary Fibrosis
Nonspecific Interstitial Pneumonitis
Hypersensitivity Pneumonitis
Cryptogenic Organizing Pneumonia (COP)
Sarcoidosis
Acute Interstitial Pneumonitis
By Drug Type (Revenue, USD Bn, 2021-2033)
Corticosteroids
Anti-fibrotic Medication
Pirfenidone
Nintedanib
By Distribution Channel (Revenue, USD Bn, 2021-2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Interstitial Lung Disease Market, By Region (Revenue, USD Bn, 2021-2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC
- Israel
- Rest of Middle East
Africa
- South Africa
- Central Africa
- North Africa
Key Players
MSD (Merck)
Liminal Biosciences
Glenmark Pharma
Chemicals & Pharmaceuticals
Boehringer Ingelhim International GmbH
Hoffmann-La Roche Ltd.
Cipla

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Disease Type
- Market Snapshot, By Drug Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Key Developments
Disease Type Approval
Collaboration/Merge/Acquisition
Regulatory Landscape
PEST Analysis
Porter's Five Forces Analysis
Epidemiology
Robust Pipeline Analysis

4. Global Interstitial Lung Disease Market, By Disease Type, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
Interstitial Pneumonia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Idiopathic Pulmonary Fibrosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Nonspecific Interstitial Pneumonitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Hypersensitivity Pneumonitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Cryptogenic Organizing Pneumonia (COP)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Sarcoidosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Acute Interstitial Pneumonitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

5. Global Interstitial Lung Disease Market, By Drug Type, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Anti-fibrotic Medication
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Pirfenidone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Nintedanib
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

6. Global Interstitial Lung Disease Market, By Distribution Channel, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

7. Global Interstitial Lung Disease Market, By Region, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Billion)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Heat Map Analysis
Market Share Analysis
Company Profile
- MSD (Merck)
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Liminal Biosciences
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Glenmark Pharma
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- B. Chemicals & Pharmaceuticals
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Boehringer Ingelhim International GmbH
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- F. Hoffmann-La Roche Ltd.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Cipla
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
Analyst Views